STAT3 and inflammatory bowel disease: This process not only promotes STAT3 phosphorylation and nuclear translocation but also aggravates intestinal inflammatory response and intestinal barrier damage, Therefore, controlling the intake of LCFAs is a potential strategy for the prevention and treatment of IBD (144).